Skip to main content
Top
Published in: International Journal of Clinical Oncology 3/2013

01-06-2013 | Original Article

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy

Authors: Kyoichi Kaira, Toshiaki Takahashi, Haruyasu Murakami, Takehito Shukuya, Hirotsugu Kenmotsu, Akira Ono, Tateaki Naito, Asuka Tsuya, Yukiko Nakamura, Masahiro Endo, Haruhiko Kondo, Takashi Nakajima, Nobuyuki Yamamoto

Published in: International Journal of Clinical Oncology | Issue 3/2013

Login to get access

Abstract

Background

The aim of this study is to evaluate whether class III β-tubulin (TUBB3) expression could predict progression-free survival or overall survival in relapsed non-small cell lung cancer (NSCLC) patients treated with taxene-based chemotherapy.

Methods

Immunohistochemistal staining was used to examine the expression of TUBB3 in resected lung tumor specimens obtained from 56 patients treated with platinum-based chemotherapy against recurrent tumors after curative resections. Excision repair cross-complementation group 1, breast cancer susceptibility gene 1, vascular endothelial growth factor, Ki-67, CD34, and p53 were also correlated with clinical features and outcome after treatment.

Results

Of the 56 patients enrolled in the study, 29 were treated by carboplatin plus paclitaxel as first-line treatment, and 24 patients received docetaxel monotherapy as second- or third-line treatment. A positive TUBB3 expression is closely associated with a poor response to taxane-based chemotherapy. TUBB3 expression was an independent prognostic factor for predicting poor progression-free survival after docetaxel administration. However, TUBB3 expression could not predict outcome after carboplatin plus paclitaxel treatment. The other biomarkers tested were not independent prognostic factors for predicting outcome after taxane-based chemotherapy.

Conclusion

TUBB3 expression is associated with resistance to taxane-based chemotherapy and is an independent prognostic factor for predicting poor progression-free survival after docetaxel treatment alone. TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease.
Literature
1.
go back to reference Kawaguchi T, Takada M, Kubo A et al (2010) Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer. A comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 5:620–630PubMed Kawaguchi T, Takada M, Kubo A et al (2010) Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer. A comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 5:620–630PubMed
2.
go back to reference Kaira K, Yamamoto N (2010) Prognostic and predictive factors in resected non-small cell lung cancer. Expert Opin Med Diagn 4:1–9CrossRef Kaira K, Yamamoto N (2010) Prognostic and predictive factors in resected non-small cell lung cancer. Expert Opin Med Diagn 4:1–9CrossRef
3.
go back to reference Jordan MA, Wilson L (2001) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265CrossRef Jordan MA, Wilson L (2001) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265CrossRef
4.
go back to reference Kang CH, Jang BG, Kim DW et al (2010) The prognostic significance of ERCC1, XRCC1, and β III-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68:478–483PubMedCrossRef Kang CH, Jang BG, Kim DW et al (2010) The prognostic significance of ERCC1, XRCC1, and β III-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68:478–483PubMedCrossRef
5.
go back to reference Seve P, Reiman T, Dumontet C (2010) The role of βIII-tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67:136–143 Seve P, Reiman T, Dumontet C (2010) The role of βIII-tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67:136–143
6.
go back to reference Azuma K, Sasada K, Kawahara A et al (2009) Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:326–333PubMedCrossRef Azuma K, Sasada K, Kawahara A et al (2009) Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:326–333PubMedCrossRef
7.
go back to reference Rosell R, Scagliotti G, Danenberg KD et al (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small cell lung cancer. Oncogene 22:3548–3552PubMedCrossRef Rosell R, Scagliotti G, Danenberg KD et al (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small cell lung cancer. Oncogene 22:3548–3552PubMedCrossRef
8.
go back to reference Dumontet C, Isaac S, Souquet PJ et al (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92:E25–E30PubMed Dumontet C, Isaac S, Souquet PJ et al (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92:E25–E30PubMed
9.
go back to reference Seve P, Issac S, Tredan O et al (2005) Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481–5486PubMedCrossRef Seve P, Issac S, Tredan O et al (2005) Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481–5486PubMedCrossRef
10.
go back to reference Seve P, Mackey J, Issac S et al (2005) Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001–2007PubMedCrossRef Seve P, Mackey J, Issac S et al (2005) Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001–2007PubMedCrossRef
11.
go back to reference Hayashi Y, Kuriyama H, Umezu H et al (2009) Class III β-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med 48:203–208PubMedCrossRef Hayashi Y, Kuriyama H, Umezu H et al (2009) Class III β-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med 48:203–208PubMedCrossRef
12.
go back to reference Volker M, Mone MJ, Kamakar P et al (2001) Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 8:213–224PubMedCrossRef Volker M, Mone MJ, Kamakar P et al (2001) Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 8:213–224PubMedCrossRef
13.
go back to reference Simon GR, Sharma S, Cantor A et al (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978–983PubMedCrossRef Simon GR, Sharma S, Cantor A et al (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978–983PubMedCrossRef
14.
go back to reference Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRef Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRef
15.
go back to reference Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808PubMedCrossRef Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808PubMedCrossRef
16.
go back to reference Mountain CF (1997) Revision in the International System for Staging Lung Cancer. Chest 11:1710–1717CrossRef Mountain CF (1997) Revision in the International System for Staging Lung Cancer. Chest 11:1710–1717CrossRef
17.
go back to reference Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef
18.
go back to reference Koh Y, Jang B, Han SW et al (2010) Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 5:320–325PubMedCrossRef Koh Y, Jang B, Han SW et al (2010) Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 5:320–325PubMedCrossRef
19.
go back to reference Skov BG, Holm B, Erreboe A et al (2010) ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 5:453–459PubMedCrossRef Skov BG, Holm B, Erreboe A et al (2010) ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 5:453–459PubMedCrossRef
20.
go back to reference Kaira K, Endo M, Abe M et al (2010) Biologic correlation of 2-[18F]-fluoro-2-deoxy-d-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28:3746–3753PubMedCrossRef Kaira K, Endo M, Abe M et al (2010) Biologic correlation of 2-[18F]-fluoro-2-deoxy-d-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28:3746–3753PubMedCrossRef
21.
go back to reference Kaira K, Oriuchi N, Shimizu K et al (2008) Evaluation of thoracic tumors with 18F-FMT and 18F-FDG PET-CT: a clinicopathological study. Int J Cancer 124:1152–1160CrossRef Kaira K, Oriuchi N, Shimizu K et al (2008) Evaluation of thoracic tumors with 18F-FMT and 18F-FDG PET-CT: a clinicopathological study. Int J Cancer 124:1152–1160CrossRef
22.
go back to reference Kaira K, Oriuchi N, Imai H et al (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98:742–748PubMedCrossRef Kaira K, Oriuchi N, Imai H et al (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98:742–748PubMedCrossRef
23.
go back to reference Davies AM, Lara PN Jr, Mack PC et al (2003) Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother 4:553–565PubMedCrossRef Davies AM, Lara PN Jr, Mack PC et al (2003) Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother 4:553–565PubMedCrossRef
24.
go back to reference Maio MD, Chiodini P, Georgoulias V et al (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836–1843PubMedCrossRef Maio MD, Chiodini P, Georgoulias V et al (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836–1843PubMedCrossRef
25.
go back to reference Azuma K, Komohara Y, Sasada T et al (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336–1343PubMedCrossRef Azuma K, Komohara Y, Sasada T et al (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336–1343PubMedCrossRef
26.
go back to reference Vilmar A, Santoni-Rugiu E, Sørensen JB (2010) ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 13:1554–1562CrossRef Vilmar A, Santoni-Rugiu E, Sørensen JB (2010) ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 13:1554–1562CrossRef
27.
go back to reference Sekine I, Nokihara H, Yamamoto N et al (2009) Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol 4:518–521PubMedCrossRef Sekine I, Nokihara H, Yamamoto N et al (2009) Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol 4:518–521PubMedCrossRef
Metadata
Title
The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy
Authors
Kyoichi Kaira
Toshiaki Takahashi
Haruyasu Murakami
Takehito Shukuya
Hirotsugu Kenmotsu
Akira Ono
Tateaki Naito
Asuka Tsuya
Yukiko Nakamura
Masahiro Endo
Haruhiko Kondo
Takashi Nakajima
Nobuyuki Yamamoto
Publication date
01-06-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-012-0386-8

Other articles of this Issue 3/2013

International Journal of Clinical Oncology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine